Some mutations in tumour cells play no part in causing cancer, but they generate cellular weak spots that may allow tumour cells to be selectively killed by drugs. See Article p.337
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Muller, F. L. et al. Nature 488, 337–342 (2012).
Sellers, W. R. Cell 147, 26–31 (2011).
Workman, P. & de Bono, J. Curr. Opin. Pharmacol. 8, 359–362 (2008).
Stratton, M. R., Campbell, P. J. & Futreal, P. A. Nature 458, 719–724 (2009).
Vavouri, T., Semple, J. I. & Lehner, B. Trends Genet. 24, 485–488 (2008).
Kafri, R., Bar-Even, A. & Pilpel, Y. Nature Genet. 37, 295–299 (2005).
Burga, A., Casanueva, M. O. & Lehner, B. Nature 480, 250–253 (2011).
Lehner, B. Trends Genet. 27, 323–331 (2011).
Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W. & Friend, S. H. Science 278, 1064–1068 (1997).
Chan, D. A. & Giaccia, A. J. Nature Rev. Drug Discov. 10, 351–364 (2011).
Nijhawan, D. et al. Cell http://dx.doi.org/10.1016/j.cell.2012.07.023 (2012).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lehner, B., Park, S. Exploiting collateral damage. Nature 488, 284–285 (2012). https://doi.org/10.1038/488284a
Published:
Issue Date:
DOI: https://doi.org/10.1038/488284a
